The 30-second summary
- Food noise has a proper definition now: persistent, unwanted thoughts about food that intrude on everyday life. GLP-1 medicines reduce it for many people.
- No study we could find has measured it coming back. The likely reasons, from the dose you are on to sleep, your cycle and long gaps between meals, each have evidence of their own.
- After stopping, appetite returns for most people. Plan for it with your prescriber rather than waiting to find out.
What food noise is
For years it was dismissed as a lack of willpower. In 2025, a group of researchers who study it proposed a formal definition: persistent thoughts about food that the person perceives as unwanted or distressing, and that may cause social, mental or physical harm. What separates it from ordinary thoughts about lunch is its intensity and intrusiveness, which the authors compare to rumination.
It can now be measured. A five-item Food Noise Questionnaire was developed and tested in 400 adults in 2025, and proved reliable when people filled it in twice a week apart. Not everyone is convinced the concept is settled: a 2026 commentary in Appetite argues that food noise overlaps with older ideas such as cravings and food preoccupation, and needs clearer definition before it is used clinically. Both things can be true. The experience is real, and the science of it is young. (See food noise.)
What GLP-1 medicines do to it
- Semaglutide 2.4 mg. In a 20-week trial, people reported fewer and weaker food cravings and better control of eating than on placebo.
- Semaglutide 1 mg. In a 12-week trial, people had less hunger, fewer cravings and better control of eating.
- Tirzepatide. In a 6-week trial, people reported less craving, less tendency to overeat and less reaction to food around them than on placebo.
- In everyday use. A 2026 survey of 550 US adults taking semaglutide, whose authors included staff of its manufacturer, found the median Food Noise Questionnaire score fell from 13 out of 20 before treatment to 6 after. People were remembering how they felt before, which is a real weakness, so treat the size of that drop with care.
In a 2026 study of 30 people interviewed about their experience, reduced food noise was one of the main themes.
Why it can come back while you are still taking it
We could find no study that has followed food noise returning in people who stay on these medicines. These are the likely reasons, each with evidence of its own.
1. The dose, and where you are in the week. Starting doses are low, and blood levels fall between injections: semaglutide has a half-life of about a week and tirzepatide about 5 days, according to their prescribing information. If the noise returns in the day or two before your injection, write it down and tell your prescriber. (See still hungry on Mounjaro or Wegovy.)
2. Reaching a stable weight. In a 2026 study that interviewed 31 people on obesity medicines, those still losing weight described strong appetite suppression and reduced food noise. Some described a perceived loss of effect, and some, especially among those whose weight had stabilised, were considering switching medicines. That is what people said, not a measurement.
3. Poor sleep. A 2017 meta-analysis found that when people's sleep was cut short, they ate about 385 kcal a day more, with more fat and less protein. A run of bad nights can sound a lot like food noise.
4. The week before your period. A 2025 meta-analysis found women ate about 168 kcal a day more in the luteal phase, the two weeks before a period. (See the menstrual cycle and GLP-1 medicines.)
5. Long gaps without food. A 2025 joint advisory from four US nutrition and obesity medicine societies notes that less interest in food can lead people to go several hours without eating, which for some brings a rebound pull towards sugary foods and refined carbohydrates once they become overly hungry.
6. Stress and emotion. A 2026 review of weight regain lists emotional, stress-related and pleasure-driven eating among the behavioural drivers of relapse.
What happens after stopping
This part is clearer. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of their body weight over the following year. (See what happens when you stop a GLP-1.)
A 2026 review in eClinicalMedicine describes what drives that: the appetite suppression reverses, hunger hormones shift towards eating more, with ghrelin rising and leptin, peptide YY and cholecystokinin falling, and the body burns a little less. We could find no study that has measured food noise itself after stopping, but the direction is not in doubt.
If you are thinking about stopping, a 2026 trial tested a middle path: dropping tirzepatide to a lower dose kept off more weight than stopping, though less than staying on the full dose. (See staying on a lower GLP-1 dose.)
What helps
- Regular meals with protein. A 2020 meta-analysis of short-term trials found higher-protein meals reduced hunger and increased fullness. Eat every 3 to 4 hours rather than holding out. (See protein on a GLP-1.)
- Fibre at each meal. A 2011 systematic review found some types of fibre, especially the more viscous ones, reduced appetite, though the effects were small. Have it with enough fluid. (See fibre on a GLP-1.)
- Protect your sleep. Given the evidence above, it may do more for food noise than any food rule.
- Plan the predictable weeks. The days before your injection or your period are easier to manage when you know they are coming.
- Consider psychological support. The 2026 review points to cognitive behavioural therapy, mindfulness and acceptance-based approaches for reactive eating, and a 2026 European consensus statement on these medicines recommends psychological screening, with support where it is needed.
- Talk to your prescriber. The same European consensus statement describes decisions to increase, delay, pause, reduce or stop these medicines as shared decisions between patient and clinician. Never change your dose yourself.
If thoughts about food feel out of control, or you find yourself restricting hard or bingeing, tell your GP. That is a reason for support, not a failure.
What to do with this
When the noise returns, a plan helps more than willpower. The calculator works out your protein floor and calorie target, so regular meals have a shape, and gives you an estimate of how much you are likely to manage at your dose.
Sources
- Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutr Diabetes 2025. PubMed
- Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity 2025. PubMed
- Brewis A, et al. Food noise: Conceptual, methodological, and ethical considerations. Appetite 2026. PubMed
- Arnaut T, et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Adv Ther 2026. PubMed
- Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021. PubMed
- Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017. PubMed
- Martin CK, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med 2025. PubMed
- de Vere Hunt I, et al. Patient Experiences With GLP-1 Receptor Agonists. JAMA Netw Open 2026. PubMed
- Chong MC, et al. Changes in Eating Behaviour During Treatment With Obesity Medications. Clin Obes 2026. PubMed
- Al Khatib HK, et al. The effects of partial sleep deprivation on energy balance: a systematic review and meta-analysis. Eur J Clin Nutr 2017. PubMed
- Tucker JAL, et al. The Effect of the Menstrual Cycle on Energy Intake: A Systematic Review and Meta-analysis. Nutr Rev 2025. PubMed
- Moiz A, et al. Weight maintenance after discontinuation of GLP-1 therapies. eClinicalMedicine 2026. PubMed
- Dobbie LJ, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults: an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol 2026. PubMed
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022. PubMed
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024. PubMed
- Kohanmoo A, et al. Effect of short- and long-term protein consumption on appetite and appetite-regulating gastrointestinal hormones, a systematic review and meta-analysis of randomized controlled trials. Physiol Behav 2020. PubMed
- Wanders AJ, et al. Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials. Obes Rev 2011. PubMed
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity Pillars 2025. PubMed
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Never change your dose without talking to your prescriber. See our full medical disclaimer.